Table 2. Parameters associated with recommended candidemia treatment and results, n = 283.

Variable		With IDC		Without IDC		OR (95% CI)		P value
		(n = 126, 44.5%)		(n = 157, 55.1%)
Definitive antifungal therapy	Appropriate antifungal choice (n = 276) a	120/124	(96.8)	125/152	(82.2)	6.48	(2.20–19.07)	<0.001
	Liposomal amphotericin b	4	(3.2)	3	(2.0)	1.66	(0.36–7.54)	0.70
	Fluconazole	51	(41.1)	19	(12.5)	4.89	(2.69–8.90)	<0.001
	Echinocandin	9	(7.3)	12	(7.9)	0.91	(0.37–2.24)	0.84
	Voriconazole	0	(0.0)	3	(2.0)			0.26
	Appropriate planned duration of antifungal therapy (n = 280)b	105/125	(84.0)	89/155	(57.4)	3.89	(2.19–6.92)	<0.001
	Median duration of antifungal therapyb	19	(15–31)	14	(6–20)			<0.001
Intervention	Transthoracic echocardiogram	22	(17.5)	1	(0.6)	33.00	(4.38–248.59)	<0.001
	Adequate source control	106	(84.1)	130	(82.8)	1.10	(0.59–2.07)	0.77
	CVC removal	86	(68.3)	120	(76.4)	0.66	(0.39–1.12)	0.12
	Early CVC removal (≤ 48 hours)	65	(51.6)	102	(65.0)	0.58	(0.36–0.93)	0.023
	Peripheral-line removal	17	(13.5)	8	(5.1)	2.91	(1.21–6.97)	0.013
	Intra-abdominal drainage	3	(2.4)	2	(1.3)	1.89	(0.31–11.49)	0.66
	Consultation to Ophthalmologist	98	(77.8)	54	(34.4)	6.68	(3.92–11.38)	<0.001
	Performed the ecocardiography	22	(17.5)	1	(0.6)	33.00	(4.38–248.59)	<0.001

Unless otherwise stated, data are presented as n (%)

IDC, infectious disease consultation; OR, odds ratio; CI, confidence interval; IQR, interquartile range; CVC, central venous catheter

^aAppropriate antifungal choice was unspecified for 7patients due to unclassified Candida species.

^bDuration of therapy was unspecified for 3 patients.